Skip to main content
. 2022 Feb 21;14(2):461. doi: 10.3390/pharmaceutics14020461

Figure 1.

Figure 1

(A) Pharmacological treatment of the Cluster A patients (number of patients = 211). Rac-methadone, at the first visit, represented the preferred option. F = female, M = male, TOT = total aggregated data. Patient distribution on drug therapy at recruitment (B) and after 21 months of COVID-19, during the pandemic period. (C) Rac-methadone (MET), LEVO = levomethadone.